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Secondary hyperparathyroidism is associated with mortality
in patients undergoing maintenance dialysis treatment. We
studied 515 male US veterans with chronic kidney disease,
who were not yet on dialysis, to see what outcomes were
associated with secondary hyperparathyroidism in this
population. Relationships between intact parathyroid
hormone levels and all-cause mortality along with the
composite of mortality or incidence of dialysis were
measured in unadjusted and adjusted Cox models for case-
mix and laboratory variables. Elevated parathyroid hormone
levels above the upper limit compared to the lower limit of
the normal range were significantly associated with mortality
after adjustments. Higher intact parathyroid hormone levels
in the upper limit of normal were significantly associated
with higher mortality overall and showed similar trends in
subgroups of patients with stage 3 and stage 4–5 chronic
kidney disease and with higher and lower serum calcium and
phosphorus levels. Similar associations were found with the
composite outcome of mortality or dialysis. Our study shows
that secondary hyperparathyroidism is independently
associated with higher mortality in patients with chronic
kidney disease but not yet on dialysis.
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Secondary hyperparathyroidism (SHPT) is a common
complication of chronic kidney disease (CKD)1 and has been
linked to higher cardiovascular morbidity2,3 and mortality4–6
in patients on maintenance hemodialysis. SHPT develops
gradually as kidney function deteriorates.1 Patients with
earlier stages of CKD by far outnumber those undergoing
maintenance dialysis treatment,7 but the impact on mortality
associated with SHPT in this group is unknown. It is also
unclear to what extent the outcomes linked to SHPT could be
confounded by other factors associated with higher para-
thyroid hormone (PTH) levels, such as hyperphosphatemia
(associated with higher mortality8 and more severe progres-
sion of kidney disease9,10 in CKD) and the use of activated
vitamin D (associated with better survival in dialysis
patients5,11). We examined outcomes (all-cause mortality
and the composite of predialysis mortality or initiation of
maintenance dialysis) as a function of PTH level in 515 male
US veterans with predialysis CKD stages 3–5, with special
attention to the confounding effect of hyperphosphatemia,
hypocalcemia, and treatment with activated vitamin D.
RESULTS
The patient cohort had a mean age of 69.4±10.2 years and
included 24% black patients. The mean estimated glomerular
filtration rate (GFR) was 31.1±10.9 ml per min per 1.73 m2
and the median PTH level was 103 pg ml1 (interquartile
range: 65–179 pg ml1). Baseline characteristics by categories
of PTH level are shown in Table 1. Patients with higher PTH
levels had higher blood pressure; lower estimated GFR, serum
albumin, bicarbonate, calcium, and blood hemoglobin; and
higher serum phosphorus and 24-h urine protein, and they
were more likely to use phosphate binders and activated
vitamin D. Overall, 127 patients died before starting dialysis
(mortality rate: 104/1000 patient-years, 95% confidence
interval (CI): 88–124) and 130 patients initiated dialysis
(dialysis initiation rate: 107/1000 patient-years, 95% CI:
90–127) during a median follow-up of 2.3 years. Six patients
were lost to follow-up and their characteristics were not
significantly different (data not shown).
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SHPT and all-cause mortality
PTH level was not associated with mortality in unadjusted
analyses (unadjusted hazard ratios (95% CI) for PTH 65–110,
110–179, and 4179 versus o65 pg ml1: 0.90 (0.58–1.42),
0.89 (0.54–1.46), and 0.89 (0.53–1.48); P¼ 0.6 for trend), but
higher PTH levels were associated with higher mortality after
adjustment for age, race, body mass index (BMI), smoking,
comorbidities, estimated GFR, serum calcium, phosphorus,
albumin and cholesterol levels, and the use of activated
vitamin D and calcium-containing medications (adjusted
hazard ratios (95% CI) for PTH 65–110, 110–179, and 4179
versus o65 pg ml1: 1.49 (0.91–2.43), 1.67 (0.95–2.94), and
2.00 (1.06–3.80); P¼ 0.028 for trend). Adjustment for
treatment with activated vitamin D had the largest impact
on the association between PTH and mortality (P¼ 0.4 for
linear trend before and P¼ 0.028 for linear trend after
inclusion of variable for activated vitamin D use in the
multivariable model).
Figure 1 shows the multivariable-adjusted estimated log
relative hazard of mortality associated with continuous PTH,
indicating a monotonic increase in mortality with higher
levels of serum PTH. Table 2 shows the mortality hazard ratio
(95% CI) associated with PTH when examined as a
continuous variable, along with mortality hazard ratios
(95% CI) associated with the other components included
in the multivariable Cox model. A 1 s.d. higher natural
log-transformed PTH level was associated with a fully
adjusted death hazard ratio of 1.28 (95% CI: 1.04–1.58;
P¼ 0.021).
Figure 2 shows hazard ratios of mortality associated with a
PTH level of 465 pg ml1 compared to a level of
Table 1 | Baseline characteristics of individuals stratified by categories of intact PTH level
PTH (pg ml1)
o65 (N=128) 65–110 (N=146) 111–179 (N=113) 4179 (N=128) P-value
Age (years) 68.4±10.3 70.1±9.9 71.1±9.1 68.1±11.2 0.06
Race (% Black) 26 (20) 29 (20) 29 (26) 38 (30) 0.18
DM 76 (59) 84 (58) 60 (53) 70 (55) 0.7
ASCVD 77 (60) 80 (55) 75 (66) 68 (53) 0.14
Smoking 29 (24) 30 (21) 22 (21) 39 (31) 0.2
Comorbidity index 2.3±1.6 2.6±1.9 2.4±1.4 2.7±1.7 0.2
Vitamin D analog use 16 (12) 64 (44) 87 (77) 89 (70) o0.001
Calcium-containing medication use 25 (20) 29 (20) 34 (30) 80 (62) o0.001
Sevelamer HCl use 9 (7) 19 (13) 21 (19) 43 (34) o0.001
ACEI/ARB use 100 (78) 113 (77) 78 (69) 99 (77) 0.3
Statin use 94 (73) 105 (72) 81 (72) 85 (66) 0.6
BMI (kg m2) 28.7±5.2 29.4±6.0 29.2±5.7 29.0±6.1 0.8
SBP (mm Hg) 143±26 145±24 148±27 152±25 0.02
DBP (mm Hg) 72±15 70±15 69±16 75±14 0.01
eGFR (ml per min per 1.73 m2) 35.7±10.0 34.7±10.4 30.9±8.7 22.5±9.1 o0.0001
CKD stage 3/4/5 91 (71)/33 (26)/4 (3) 96 (66)/46 (32)/4 (3) 60 (53)/49 (43)/4 (4) 23 (18)/76 (59)/29 (23) o0.0001
Serum albumin (g per 100 ml) 3.6±0.4 3.6±0.5 3.6±0.4 3.4±0.5 0.005
Serum cholesterol (mg per 100 ml) 181±46 186±49 179±49 190±53 0.23
Serum bicarbonate (mg per 100 ml) 26.0±3.1 26.3±3.0 26.0±3.6 24.0±3.9 o0.0001
Serum calcium (mg per 100 ml) 9.4±0.6 9.2±0.5 9.2±0.5 8.8±0.7 o0.0001
Serum phosphorus (mg per 100 ml) 3.9±0.7 3.8±0.6 4.0±0.7 4.4±0.9 o0.0001
Blood Hgb (g per 100 ml) 12.7±1.8 12.8±1.6 12.4±1.7 11.8±1.7 o0.0001
Blood WBC (1000 mm3) 7.4±2.4 7.5±2.5 7.4±2.0 7.2±2.2 0.7
Blood lymphocytes (% WBC) 24.3±8.4 21.8±7.9 22.5±7.8 22.4±8.4 0.08
Proteinuria (g per 24 h) 613 (476–790) 526 (418–660) 488 (381–627) 1404 (1094–1801) o0.0001
ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CI, confidence
interval; CKD, chronic kidney disease; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; Hgb, hemoglobin; SBP, systolic blood
pressure; WBC, white blood cell count.
Data are presented as means±s.d., number (% of total), or geometric means (95% CI).
Comparisons are made by ANOVA or w2 test.
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Figure 1 | Estimated log relative hazards of all-cause mortality for
continuous PTH in a multivariable regression spline model
adjusted for age, race, BMI, smoking status, Charlson
comorbidity index, diabetes mellitus, use of activated vitamin D
and calcium-containing medications, estimated GFR, and serum
levels of calcium, phosphorus, albumin and cholesterol. Dashed
lines, 95% pointwise CIs.
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p65 pg ml1, overall and in selected subgroups. A PTH level
of 465 pg ml1 was associated with higher mortality overall,
and similar trends were present in the studied subgroups,
albeit without reaching statistical significance in most; this
association was less pronounced in diabetic patients, but the
interaction with diabetes mellitus was not statistically
significant. A PTH level of 465 pg ml1 tended to be
associated with higher mortality in both patients who never
received an activated vitamin D product (adjusted hazard
ratio: 1.47 (95% CI: 0.89–2.41)) and in patients who received
such treatment (adjusted hazard ratio: 2.40 (95% CI:
0.55–10.47)), although none of these associations reached
statistical significance; there was also no statistically
significant interaction with activated vitamin D treatment
status. Patients with CKD stages 4 and 5 showed a stronger
association between PTH 465 pg ml1 and mortality
(adjusted hazard ratio: 2.10 (95% CI: 0.99–4.45)) compared
to patients with CKD stage 3 (adjusted hazard ratio: 1.32
(95% CI: 0.72–2.44)), but no statistically significant inter-
action with CKD stage was present. Figure 3 shows the
multivariable-adjusted estimated log relative hazard of
mortality associated with continuous PTH in subgroups
of patients with CKD stage 3 and stages 4 and 5, indicating an
increase in mortality with higher levels of serum PTH level in
both subgroups.
The composite end point of predialysis mortality or
end-stage renal disease also showed an association with
higher PTH, with adjusted hazard ratios of the composite
end point (95% CI) for PTH 65–110, 110–179, and 4179
versus o65 pg ml1 being 1.30 (0.88–1.90), 1.69 (1.11–2.58),
and 1.83 (1.17–2.85), P¼ 0.004 for trend. Figure 4 shows the
multivariable-adjusted estimated log relative hazard of the
combined end point associated with continuous PTH,
indicating a monotonic increase in mortality with higher
levels of serum PTH level.
DISCUSSION
SHPT develops early and shows a progressive worsening
during the course of CKD.1 Higher PTH levels have been
associated with multiple complications, including bone
disease,12,13 uremic pruritus,14 cognitive and sexual dysfunc-
tion,15,16 and higher cardiovascular morbidity2,3,17 and
mortality.4–6 The higher morbidity and mortality associated
with SHPT has been described in patients receiving
maintenance hemodialysis, but it is unclear if the same
associations hold true in patients with earlier stages of CKD.
We described outcomes associated with higher PTH levels in
a cohort of male patients with CKD stages 3–5 who were not
yet on dialysis, and found that once we accounted for the
All
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Figure 2 | Multivariable adjusted hazard ratios (95% CIs) of all-cause mortality associated with an intact PTH level 465 pg ml1
compared to o65 pg ml1, overall and in selected subgroups. Models were adjusted for age, race, BMI, smoking status, Charlson
comorbidity index, diabetes mellitus, use of activated vitamin D and calcium-containing medications, estimated GFR, and serum levels of
calcium, phosphorus, albumin and cholesterol.
Table 2 | Hazard ratios of all-cause mortality for variables
included in the multivariable Cox model
Hazard ratio 95% CI
PTH 1.28 1.04–1.58
Age 1.80 1.39–2.31
Black race (referent: white race) 0.97 0.62–1.51
BMI 0.78 0.62–0.98
Active smoking (referent: non-smoking) 1.92 1.21–3.05
Comorbidity index 1.31 1.08–1.59
DM (referent: no DM) 1.37 0.90–2.06
Activated vitamin D use (referent: no
activated vitamin D use)
0.28 0.18–0.42
Calcium use (referent: no calcium use) 0.31 0.18–0.52
eGFR 0.88 0.69–1.13
Serum calcium 1.10 0.89–1.35
Serum phosphorus 1.65 1.30–2.09
Serum albumin 0.61 0.49–0.75
Serum cholesterol 0.81 0.66–0.99
BMI, body mass index; CI, confidence interval; DM, diabetes mellitus; eGFR,
estimated glomerular filtration rate; PTH, parathyroid hormone.
Shown for all continuous variables are hazard ratios (95% CIs) associated with a 1 s.d.
higher level of the variable.
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effect of potential confounders, higher PTH was associated
with higher all-cause predialysis mortality. These results were
present even after adjustment for potential confounders such
as serum phosphorus and calcium levels and the use of
activated vitamin D therapy, suggesting that SHPT is
associated with mortality independent of the effect of
concomitant hyperphosphatemia or vitamin D therapy. We
found significant negative confounding by the treatment
status with activated vitamin D products in the association
between PTH levels and mortality. This is not surprising, as
these agents were used more often in patients with higher
PTH levels and their main effect is the lowering of PTH
levels, and also their application is independently associated
with favorable outcomes.18 A similar negative confounding
phenomenon was previously described in a study examining
the association of PTH and mortality in patients with CKD
on dialysis.5
The association of higher PTH levels with higher mortality
in our study was linear and strictly up going, without a
discernible upper or lower threshold level. The higher risk of
mortality was evident above the upper limit of the normal
range for PTH (465 pg ml1) in all the examined subgroups,
even though the associations were not uniformly statistically
significant because of lower patient numbers and event rates
in some of these subgroups. Patients with an estimated GFR
o30 ml per min per 1.73 m2 (CKD stages 4 and 5) also
showed higher mortality associated with PTH levels
465 pg ml1. Currently, the Kidney/Dialysis Outcome
Quality Initiative (K/DOQI) bone and mineral metabolism
guidelines recommend an intact PTH level of 70–110 pg ml1
for patients with CKD stage 4.19 Our observation is in
disagreement with this opinion-based guideline; further
research may be necessary to clarify what the ideal treatment
targets should be for SHPT. The lack of a lower threshold
level for mortality risk in our study is in contrast to studies in
dialysis where the association of PTH level with mortality was
U-shaped and showing higher mortality in patients with low
PTH levels.5,20 A significant proportion of this inverse
association in dialysis patients was, however, related to
confounding by markers of malnutrition and inflammation,5
and patients with earlier stages of CKD (such as ours) have
significantly lower PTH levels compared to those on dialysis1
and hence low PTH levels would more likely be normal
rather than confounded by pathologic states such as
malnutrition and inflammation.
The mechanism of the higher mortality seen in patients
with higher PTH levels is speculative. Elevated PTH levels
have been shown to induce a wide range of cardiovascular,
metabolic, hematologic, and immunologic abnormalities.
These include lower cardiac contractility, myocardial calcium
deposition, hypertrophy and fibrosis and vascular calcifica-
tion,21 mitral annular calcification,22 impaired insulin
sensitivity23 and glucose intolerance,24 abnormal lipid
metabolism,25 bone marrow fibrosis26 with ineffective
erythropoiesis,27 and abnormal immune function.28 Animal
models showed that PTH increases the myocardial calcium
content and adversely affects energy utilization in myocardial
tissue29 and that it could play a role in myocardial fibrosis,30
impaired vasodilatation,31 and blood pressure-independent
wall thickening of the intramyocardial arterioles.32 In a
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Figure 3 | Estimated log relative hazards of all-cause mortality for continuous PTH in a multivariable regression spline model in
subgroups of patients with CKD stage 3 and stages 4–5, adjusted for age, race, BMI, smoking status, Charlson comorbidity index,
diabetes mellitus, use of activated vitamin D and calcium-containing medications, estimated GFR, and serum levels of calcium,
phosphorus, albumin and cholesterol. Dashed lines, 95% pointwise CIs.
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Figure 4 | Estimated log relative hazards of the composite
outcome of predialysis all-cause mortality and end-stage renal
disease for continuous PTH in a multivariable regression spline
model, adjusted for age, race, BMI, smoking status, Charlson
comorbidity index, diabetes mellitus, estimated GFR, serum
levels of calcium, phosphorus, albumin and cholesterol,
proteinuria, and the use of activated vitamin D, angiotensin-
converting enzyme inhibitors, statins and calcium-containing
medications. Dashed lines, 95% pointwise CIs.
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population-based cross-sectional study, higher PTH level was
predictive of coronary heart disease.33 These data suggest that
the higher mortality associated with SHPT seen in our study
could have been resulting from higher cardiovascular
mortality related to coronary ischemia, arrhythmias, left
ventricular hypertrophy, or congestive heart failure, or from
higher infectious disease mortality.
Our study has several limitations. The design of the study
(historical cohort) does not allow us to infer causality but
merely associations. We examined exclusively male patients
from a single institution; hence, our results may not apply to
female subjects or patients from other geographical areas. We
used a single baseline PTH level to categorize patients as
having SHPT, which could have led to misclassification.
Estimation of kidney function (rather than GFR measure-
ment) could also have led to residual confounding by the
level of kidney function. Our results could have been affected
by confounding related to better care, as higher PTH could
have been a surrogate marker of suboptimal care. Patients
with higher PTH were, however, more likely to receive
interventions such as activated vitamin D and phosphate
binders, and they were equally likely to receive other
interventions frequently used in CKD (angiotensin-conver-
ting enzyme inhibitors and statins), making it less likely that
they were neglected in other areas of their care. Therapy with
activated vitamin D had a significant impact on the
association between PTH and mortality through negative
confounding, making it difficult to examine the effect of
untreated SHPT on outcomes. In the subgroup of patients
who were not treated with activated vitamin D therapy, the
association between PTH level and mortality showed a trend
similar to the overall group, but PTH levels in this subgroup
were significantly lower, making it difficult to derive
conclusions about the natural history of patients with higher
PTH levels. We speculated that the higher all-cause mortality
seen in association with SHPT in our cohort might have been
related to cardiovascular causes or infectious causes, but we
did not have recordings of causes of death to test this
hypothesis. The relatively smaller number of patients in our
cohort limited our ability to detect statistically significant
associations in subgroup analyses.
In summary, we describe an independent and graded
association between higher PTH levels and higher all-cause
mortality in patients with CKD stages 3–5 who are not yet on
dialysis. These findings complement earlier results gained
from hemodialysis patients and should form the basis of
clinical trials to prove that treatment of SHPT could lower
mortality in CKD.
MATERIALS AND METHODS
Study population and data collection
Data were collected retrospectively from 1012 patients who were
managed for CKD at Salem VA Medical Center (VAMC) between 1
January 1990 and 31 March 2007. Eleven (1.1%) female patients and
five (0.5%) patients whose race was other than White or Black were
excluded. Of the remaining 996 patients, 543 (54.5%) had at least
one serum intact PTH level measured before the initiation of
maintenance dialysis. We excluded another 22 (4%) patients whose
first serum PTH measurement was performed after 10 August 2005
(when the assay for intact PTH measurement was changed at Salem
VAMC), given the significant inter-method variability between
different PTH assays.34 Only six patients had an estimated GFR of
460 ml per min per 1.73 m2, and they were also excluded. The final
cohort consisted of 515 patients.
Participants’ baseline characteristics were recorded at the time
when the first PTH measurement occurred, and they included
demographic and anthropometric measures, blood pressure,
comorbid conditions (including the Charlson comorbidity index),
treatments at any time during the follow-up period with activated
vitamin D and calcium- and non-calcium-based phosphate binders,
and laboratory results, as detailed elsewhere.35,36 The use of
angiotensin-converting enzyme inhibitors or angiotensin receptor
blockers and HMG-CoA inhibitors (statins) was examined as a
surrogate marker of health-care quality to address the possibility
that more frequent use of activated vitamin D or phosphate binders
might indicate better medical care independent of the primary
indications for these agents. GFR was estimated using the
abbreviated equation developed for the Modification of Diet in
Renal Disease Study37 and categorized according to the staging
system introduced by the K/DOQI Clinical Practice Guidelines for
CKD: Evaluation, Classification, and Stratification.38 Serum calcium
concentration was corrected for serum albumin concentration
using the following formula:39 corrected calcium¼measured
calciumþ 0.8(4serum albumin level in g per 100 ml).
Intact PTH was measured in the clinical laboratory at Salem
VAMC by the Allegro-intact PTH assay (Nichols Institute, San
Clemente, CA, USA), with a normal range of 10–65 pg ml1 and a
coefficient of variation of o3.4%.
Statistical analyses
Variables with skewed distribution (proteinuria and PTH level) were
transformed to their natural logarithm. Missing data points for
comorbidity index (1% missing), BMI (4.8% missing), serum
phosphorus (0.2% missing), 24-h urine protein (1% missing), blood
cholesterol (1.7% missing), white blood cell count (3.7% missing),
percent lymphocytes (3.7% missing), and serum albumin (0.8%
missing) were imputed using linear regression, with all other patient
characteristics serving as independent variables. Smoking status (3%
missing) was analyzed as a categorical variable with the introduction
of a dummy variable for missing smoking status.
Survival modeling. The starting time for survival analysis was
the date of the first PTH measurement, and patients were followed
until death or loss of follow-up, with the recording of initiation
of maintenance hemodialysis. The main outcome measure was
predialysis all-cause mortality, and the secondary outcome was
the composite of predialysis mortality and end-stage renal disease
(defined as the initiation of maintenance dialysis). Deaths were
recorded from the VA Computerized Patient Record System and
cross-checked against death certificate-based records from the
National Death Index. Initiation of end-stage renal disease was
recorded from local medical records at Salem VAMC and included
reviews of Medicare Form 2728. Patients were considered lost to
follow-up if no contact was documented with them for more than
6 months and they were censored in survival analyses at the date
of the last documented contact with the medical center. PTH levels
were analyzed both as a natural log-transformed continuous
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measure and after categorization by levels based on the K/DOQI
guidelines, which incidentally also approximated quartile values (to
examine trends of linearity), and dichotomization using a cutoff
level of 65 pg ml1 (the upper limit of normal for the laboratory
assay). Nonlinear associations for PTH as a continuous predictor
were examined by using restricted cubic splines; to limit the
instability of such models at extreme PTH levels, model building
was restricted to PTH values between the 5th and 95th percentiles of
the studied groups. The association of baseline PTH levels with the
outcome measures was examined in unadjusted Cox models, and
the impact of potential confounders was analyzed in multivariable
Cox models. Selection of variables to be included in the multi-
variable model was performed by a multivariable regression spline
function using backward elimination of weak predictors using a
closed test approach.40 Age, race, diabetes mellitus, and serum
calcium and phosphorus levels were forced into the final model. The
proportionality assumption was tested by comparing predicted and
actual survival curves and by Schoenfeld residuals. Analyses were
repeated in subgroups divided by age, race, diabetes mellitus, any
type of activated vitamin D use, and levels of PTH, estimated GFR,
serum calcium and phosphorus. Interactions were formally tested
for by the inclusion of interaction terms. P-values less than 0.05 were
considered statistically significant. Statistical analyses were per-
formed using STATA statistical software version 10 (STATA
Corporation, College Station, TX, USA). The study protocol was
approved by the Research and Development Committee at the
Salem Veterans Affairs Medical Center.
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